Testing for HER2 in Breast Cancer : A Continuing Evolution
Joint Authors
Source
Pathology Research International
Issue
Vol. 2011, Issue 2011 (31 Dec. 2011), pp.1-16, 16 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2010-12-06
Country of Publication
Egypt
No. of Pages
16
Main Subjects
Abstract EN
Human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive factor in breast cancer.
HER2 is overexpressed in approximately 15%–20% of invasive breast carcinomas and is associated with earlier recurrence, shortened disease free survival, and poor prognosis.
Trastuzumab (Herceptin) a “humanized” monoclonal antibody targets the extracellular domain of HER2 and is widely used in the management of HER2 positive breast cancers.
Accurate assessment of HER2 is thus critical in the management of breast cancer.
The aim of this paper is to present a comprehensive review of HER2 with reference to its discovery and biology, clinical significance, prognostic value, targeted therapy, current and new testing modalities, and the interpretation guidelines and pitfalls.
American Psychological Association (APA)
Shah, Sejal& Chen, Beiyun. 2010. Testing for HER2 in Breast Cancer : A Continuing Evolution. Pathology Research International،Vol. 2011, no. 2011, pp.1-16.
https://search.emarefa.net/detail/BIM-506712
Modern Language Association (MLA)
Shah, Sejal& Chen, Beiyun. Testing for HER2 in Breast Cancer : A Continuing Evolution. Pathology Research International No. 2011 (2011), pp.1-16.
https://search.emarefa.net/detail/BIM-506712
American Medical Association (AMA)
Shah, Sejal& Chen, Beiyun. Testing for HER2 in Breast Cancer : A Continuing Evolution. Pathology Research International. 2010. Vol. 2011, no. 2011, pp.1-16.
https://search.emarefa.net/detail/BIM-506712
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-506712